Table 4.
Estimated effect (EE) and effect size (ES) of early engagement in Didactic Webinars
| Early engagement with a prescriber vs. Did not engage | Early engagement without a prescriber vs. Did not engage | Early engagement with a prescriber vs. Early engagement without a prescriber | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q1 | Q2 | Q3 | Q1 | Q2 | Q3 | |
| Reach | |||||||||
| Number of patients on OUD | |||||||||
| EE (95% CI) | −12.98 (−1565.22, 1539.26) | −7.63 (−702.28, 687.03) | −2.27 (−1554.45, 1549.91) | −4.21 (−1829.63, 1821.21) | 10.04 (−943.41, 963.50) | 24.30 (−1801.41, 1850.00) | −8.77 (−1190.90, 1173.36) | −17.67 (−635.76, 600.43) | −26.57 (−1209.28, 1156.15) |
| ES (95% CI) | −0.16 (−19.65, 19.33) | −0.10 (−8.82, 8.63) | −0.03 (−19.52, 19.46) | −0.05 (−22.97, 22.87) | 0.13 (−11.84, 12.10) | 0.31 (−22.62, 23.23) | −0.11 (−14.95, 14.73) | −0.22 (−7.98, 7.54) | −0.33 (−15.18, 14.52) |
| Number of patients prescribed MOUD | |||||||||
| EE (95% CI) | −1.29 (−44.71, 42.13) | 2.05 (−24.66, 28.77) | 5.40 (−38.03, 48.82) | 6.91 (−46.69, 60.51) | 8.81 (−27.74, 45.37) | 10.72 (−42.88, 64.32) | −8.20 (−43.00, 26.61) | −6.76 (−30.53, 17.02) | −5.32 (−40.13, 29.48) |
| ES (95% CI) | −0.08 (−2.83, 2.67) | 0.13 (−1.56, 1.82) | 0.34 (−2.41, 3.09) | 0.44 (−2.96, 3.83) | 0.56 (−1.76, 2.87) | 0.68 (−2.71, 4.07) | −0.52 (−2.72, 1.68) | −0.43 (−1.93, 1.08) | −0.34 (−2.54, 1.87) |
| Percent of patients prescribed MOUDa | |||||||||
| EE (95% CI) | 10.24 (0.28, 20.20) | −8.34 (−16.26, −0.43) | −26.93 (−35.23, −18.63) | 8.15 (3.26, 13.03) | −11.30 (−15.46, −7.15) | −30.75 (−35.54, −25.96) | 2.10 (−4.88, 9.07) | 2.96 (−2.04, 7.95) | 3.82 (−2.63, 10.28) |
| ES (95% CI) | 0.28 (0.01, 0.56) | −0.23 (−0.45, −0.01) | −0.75 (−0.98, −0.52) | 0.23 (0.09, 0.36) | −0.31 (−0.43, −0.20) | −0.85 (−0.99, −0.72) | 0.06 (−0.14, 0.25) | 0.08 (−0.06, 0.22) | 0.11 (−0.07, 0.29) |
| Adoption | |||||||||
| Number of prescribers | |||||||||
| EE (95% CI) | 1.40 (−2.89, 5.69) | 0.40 (−3.37, 4.17) | −0.60 (−4.89, 3.69) | 2.06 (−3.34, 7.47) | 1.53 (−3.34, 6.40) | 1.00 (−4.41, 6.40) | −0.66 (−4.30, 2.97) | −1.13 (−4.42, 2.16) | −1.60 (−5.24, 2.04) |
| ES (95% CI) | 0.75 (−1.56, 3.06) | 0.21 (−1.81, 2.24) | −0.32 (−2.63, 1.98) | 1.11 (−1.80, 4.01) | 0.82 (−1.80, 3.44) | 0.54 (−2.37, 3.44) | −0.36 (−2.31, 1.60) | −0.61 (−2.38, 1.16) | −0.86 (−2.82, 1.10) |
| Number of x-waivered prescribers | |||||||||
| EE (95% CI) | 1.45 (0.02, 2.88) | 1.80 (0.59, 3.01) | 2.15 (0.72, 3.58) | 1.24 (−0.62, 3.11) | 0.87 (−0.77, 2.51) | 0.49 (−1.37, 2.36) | 0.21 (−0.91, 1.33) | 0.93 (−0.04, 1.91) | 1.66 (0.54, 2.78) |
| ES (95% CI) | 0.55 (0.01, 1.09) | 0.68 (0.22, 1.14) | 0.81 (0.27, 1.36) | 0.47 (−0.24, 1.18) | 0.33 (−0.29, 0.95) | 0.19 (−0.52, 0.89) | 0.08 (−0.35, 0.50) | 0.35 (−0.02, 0.72) | 0.63 (0.20, 1.05) |
| Number of active x-waivered prescribers | |||||||||
| EE (95% CI) | 0.36 (−0.26, 0.99) | 0.46 (−0.05, 0.96) | 0.56 (−0.07, 1.18) | 0.26 (−0.55, 1.08) | 0.01 (−0.68, 0.70) | −0.24 (−1.05, 0.58) | 0.10 (−0.43, 0.63) | 0.45 (0.00, 0.90) | 0.79 (0.26, 1.32) |
| ES (95% CI) | 0.20 (−0.14, 0.53) | 0.25 (−0.02, 0.52) | 0.30 (−0.04, 0.64) | 0.14 (−0.30, 0.58) | 0.01 (−0.36, 0.38) | −0.13 (−0.57, 0.31) | 0.05 (−0.23, 0.34) | 0.24 (0.00, 0.48) | 0.43 (0.14, 0.71) |
| Percent of x-waivered prescribers | |||||||||
| EE (95% CI) | 0.81 (−0.36, 1.97) | 5.62 (4.56, 6.68) | 10.44 (9.27, 11.60) | −1.44 (−2.78, −0.09) | −0.55 (−1.79, 0.68) | 0.33 (−1.02, 1.67) | 2.24 (1.39, 3.09) | 6.18 (5.39, 6.96) | 10.11 (9.26, 10.96) |
| ES (95% CI) | 0.04 (−0.02, 0.09) | 0.26 (0.21, 0.30) | 0.47 (0.42, 0.53) | −0.07 (−0.13, −0.00) | −0.03 (−0.08, 0.03) | 0.02 (−0.05, 0.08) | 0.10 (0.06, 0.14) | 0.28 (0.25, 0.32) | 0.46 (0.42, 0.50) |
| Implementation | |||||||||
| IMAT implementation quality | |||||||||
| EE (95% CI) | – | – | 0.05 (−0.04, 0.14) | – | – | −0.09 (−0.21, 0.03) | – | – | 0.14 (0.06, 0.22) |
| ES (95% CI) | – | – | 0.08 (−0.06, 0.23) | – | – | −0.15 (−0.35, 0.05) | – | – | 0.23 (0.10, 0.36) |
aPrimary outcome; EE and ES in bold indicated 95% CI did not cross zero